profit from every $100 of sales.
$0$100
Impact BioMedical
$4.30-6.93% today
+676.3% in 1 year
1-year low $0.401-year high $8.99
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Impact BioMedical sold, what it kept, and what it did with the cash.
Sales went from $50,000 in 2022 to $32,000 in 2025, with -$11.8 million of profit last year.
SalesProfit
Impact BioMedical vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Impact BioMedical | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Impact BioMedical's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | 0 | -0 | |
| -3 | -4 | -3 | -4 | |
| -6 | -3 | -23 | -13 | |
| -7 | -4 | -25 | -12 | |
| -0.61 | -0.07 | -2.30 | -0.38 | |
| – | – | – | -1,225.0% | |
| -6,808.0% | – | – | -13,343.8% | |
| -14,102.0% | – | – | -36,993.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 46 | 45 | 20 | 17 |
| Cash | 0 | 0 | 2 | 0 |
| Total debt | 10 | 12 | 9 | – |
| Total liabilities | 14 | 16 | 13 | 2 |
| 30 | 25 | 4 | 13 | |
| 11 | 60 | 11 | 32 | |
| -14.8% | -8.4% | -142.4% | -85.6% | |
| -23.9% | -17.2% | -580.1% | -93.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -2 | -3 | -3 | -2 | |
| 0 | 0 | – | – | |
| -3 | -3 | -3 | -2 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| – | 0 | 0 | 0 |
Valuation
- –
- –
- –
- 1.6×
- 1,161.0×
- –
- –
- -5.1%
- -31.9%
- 0.0%
Profitability
- -1,225.0%
- -13,343.8%
- -36,993.8%
- -9,765.6%
- -16.8%
- -54.8%
- 831.0%
- -68.0%
- -20.4%
- 1,062.5%
Growth
- −13.8%
- –
- +66.5%
- –
- −24.4%
Financial health
- -0.0×
- 0.00
- 0.0%
- 4.2×
- 0.35
- 0.30
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 958
Bottom 6%of 889
Bottom 18%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.02 | – | – |
| Mar 27, 2026 | -0.42 | – | – |
| Nov 7, 2025 | -0.12 | – | – |
| Aug 14, 2025 | -1.18 | – | – |
| May 14, 2025 | -0.11 | – | – |
| Mar 28, 2025 | -0.42 | – | – |
| Nov 12, 2024 | -0.02 | – | – |
News
SpaceX has had limited impact on stock indexes, Goldman Sachs saysSeeking Alpha · Nov 8, 2026There's a 99% Chance That Democrats Retake the House, and History Says This Shift Will Have a Huge Impact on StocksYahoo Finance · Nov 4, 2026NVDA Stock Drops: Nvidia May Back Data Center Loan For Its Own Customer, Analyst Sees Little Impact From Intel’s Weak ReportYahoo Finance · Oct 30, 2026How AI Factory Expansion Will Impact NVIDIA (NVDA) InvestorsYahoo Finance · Oct 30, 2026The 5 big voting issues in the midterm elections that will impact your walletMarketWatch · Oct 26, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
21No pass
Benjamin Graham
39No pass
Philip Fisher
31No pass
Peter Lynch
40No pass
Joel Greenblatt
0No pass
Charlie Munger
40No pass
Terry Smith
26No pass
Questions about Impact BioMedical
Is Impact BioMedical a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Impact BioMedical AI analysis
What does Impact BioMedical do?
Impact BioMedical Inc. engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. It is in Biotechnology.
Does Impact BioMedical pay a dividend?
No. Impact BioMedical does not pay a dividend at the moment.
Is Impact BioMedical stock halal?
Yes. Impact BioMedical passes our halal screen: its business is permitted and its debt is 0% of its market value, under the 30% limit. How we check
How has Impact BioMedical stock done over the past year?
Up 676.3% over the past twelve months, to $4.30. It traded between $0.40 and $8.99 and is 52.2% below its high.
Who are Impact BioMedical's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Impact BioMedical's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.